Mercury names new VP
Mercury Computer Systems this month appointed Didier Thibaud to the post of vice president and general manager of its medical business group. Thibaud has contributed to the Chelmsford, MA, company’s growth in the European medical imaging market,
Mercury Computer Systems this month appointed Didier Thibaud to the post of vice president and general manager of its medical business group. Thibaud has contributed to the Chelmsford, MA, companys growth in the European medical imaging market, according to Jay Bertelli, president and CEO. He has served as European managing director for the medical business group, as well as manager of Mercurys French subsidiary. Thibaud will continue to manage the French subsidiary, as well as the sales and support organization for Mercurys worldwide medical business, from his Paris office.
The computers that Mercury provides to OEMs are incorporated into MRI devices, multislice CT systems, and digital radiography units. The company supplies its products to GE Medical Systems, Siemens Medical Systems, and Marconi Medical Systems.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
